Policy & Regulation
Cerveau Technologies partners with Alector Inc to understand tau pathology in treating neurodegenerative diseases
23 March 2020 -

Diagnostics company Cerveau Technologies Inc said on Friday that it has entered into a licensing agreement with Alector, with focus on using MK-6240 as an exploratory biomarker in research studies.

Under the terms of the licensing agreement, Cerveau will provide its investigational imaging agent (MK-6240) to Alector for use in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain.

NFTs are made up of aggregated tau protein and are a hallmark of several neurodegenerative diseases, including Alzheimer's disease. Cerveau's vision is to develop diagnostics and technology that positively impact patients with neurodegenerative disorders.

Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases, including two Alzheimer's disease programmes currently in the clinic.



Related Headlines